fda tirzepatide injection shortage resolved october 2 2024 GLP-1 Drugs: Removes Lilly's Zepbound® and Mounjaro® (tirzepatide injection) from its Drug List FDA says years-long tirzepatide shortage

This is a dietary supplement to address deficiencies caused by L-carnitine in the body

The Medicines and Healthcare products Regulatory Agency (MHRA) advises discontinuing these GLP-1 receptor agonists if pregnancy is planned or confirmed

Yes, the FDAs black box warning for medullary thyroid carcinoma and MEN 2 syndrome applies to the entire class of GLP-1 receptor agonists, which include liraglutide (Saxeda and Victoza), dulaglutide (Trulicity), semaglutide (Ozempic, Rybelsus, and Wegovy), and tirzepatide (Mounjaro and Zepbound)

Peptides preserve membrane fluidity and receptor function, which is important for sperm motility and oocyte signaling in fertilization, by repelling chain reactions in membrane lipids

After screening, 89 articles were selected for full-text review, of which 61 were excluded for unexpected interventions (Figure 2)